INVA vs KRSA: stock comparison and AI forecast
Innoviva, Inc. (INVA) and Korsana Biosciences, Inc. (KRSA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
INVA Innoviva, Inc.
- Price
- $19.24 -15.6% · 6M
- Market Cap
- $1.38B
- P/E Ratio
- 8.4x
- Size
- small-cap
- AI Forecast
KRSA Korsana Biosciences, Inc.
- Market Cap
- $1.39B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- INVA and KRSA have similar market capitalizations ($1.38B and $1.39B).
- INVA carries 0.35 times debt per unit of equity, against 0.12 times for KRSA.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | INVA | KRSA |
|---|---|---|
| Market Cap | $1.38B | $1.39B |
| P/E Ratio | 8.41x | – |
| P/B Ratio | 1.21x | 3.55x |
| EPS | $2.27 | $-4.95 |
| Book Value/Share | $15.75 | $8.57 |
| Revenue/Share | $0.42 | – |
| FCF/Share | $2.53 | – |
Profitability & Margins
| Metric | INVA | KRSA |
|---|---|---|
| ROE | 17.0% | – |
| ROA | 12.6% | – |
| ROIC | 11.4% | -1.2% |
| Operating Margin | 566.2% | -248.8% |
| Net Margin | 643.7% | – |
| EBT Margin | 745.2% | -178.3% |
| Tax Rate | 13.6% | – |
Financial Health
| Metric | INVA | KRSA |
|---|---|---|
| Current Ratio | 15.44x | 10.42x |
| Quick Ratio | 14.58x | – |
| D/E Ratio | 0.35x | 0.12x |
| Financial Leverage | 1.35x | 1.18x |
| Interest Coverage | 7.7x | – |
| Working Capital | $722M | $416M |
Cash Flow
| Metric | INVA | KRSA |
|---|---|---|
| Operating Cash Flow | $183M | -$52M |
| Free Cash Flow | $183M | – |
| Capital Spending | -$950K | – |
| OCF Growth YoY | -9.0% | – |
| FCF/Sales | 607.3% | – |
| CapEx/Sales | 3.2% | – |
Operational Efficiency
| Metric | INVA | KRSA |
|---|---|---|
| Asset Turnover | 0.02x | – |
| Receivables Turnover | 0.7x | – |
| Fixed Assets Turnover | 14.8x | – |
| Days Sales Outstanding | 535 days | – |
Income Statement
| Metric | INVA | KRSA |
|---|---|---|
| Total Revenue | $30M | – |
| Operating Income | $170M | -$5M |
| Net Income | $193M | – |
| R&D Expense | $20M | $2M |
| SG&A Expense | $136M | – |
Dividend & Shareholder Information
| Metric | INVA | KRSA |
|---|---|---|
| Shares Outstanding | 72M | 46M |
| Net Income Growth | 51.9% | – |
| EPS Growth | 59.9% | – |
INVA vs KRSA: stock comparison and AI forecast
Which is bigger, INVA or KRSA?
INVA and KRSA have similar market capitalizations ($1.38B and $1.39B).
Which one does Intratio's AI model rank higher, INVA or KRSA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.